Azelis Group (AZE) investor relations material

Executive summary

• Revenue grew 1.3% year-over-year in constant currency to €4.1 billion, with strong free cash flow generation and continued execution of long-term strategy, despite tariff uncertainty and softer demand.

• Organic revenue declined 1.6% due to market deterioration, but acquisitions contributed +2.9% to revenue growth.

• Gross profit was €968 million (margin 23.6%), down 6.1% year-over-year, with margin contraction from negative mix effects, especially in higher-margin Life Sciences.

• Adjusted EBITDA/EBITA was €411 million (margin 10%), down 12.7% year-over-year, with margin contraction of 117–170 basis points.

• Net profit fell to €113 million, down 37.6–40.1% year-over-year, mainly due to non-cash items, higher tax rate, and lower operating profit.

• Four strategic acquisitions completed, strengthening positions in EMEA and APAC, and expanding presence in nutraceuticals, pharma, personal care, and industrial chemicals.

Financial highlights

• Full year revenue: €4.1 billion (+1.3% constant currency, -2.4% reported); Q4 revenue: €937 million.

• Gross profit: €968 million (margin 23.6%), down 6–6.1% year-over-year.

• Adjusted EBITDA/EBITA: €411 million (margin 10%), down 12.7% year-over-year.

• Net profit: €113 million, down from €189 million in 2024.

• Free cash flow: €442 million, up 29–29.2% year-over-year; cash conversion ratio: 106%.

• Net debt: €1.6 billion; leverage ratio: 3.3x, up from 2.9x in 2024.

Outlook and guidance

• Near-term uncertainty persists, with demand weighed by macro volatility, geopolitical tensions, and trade disruptions.

• Focus remains on cost control, working capital, and cash generation, while staying agile to capture growth when the cycle turns.

• Medium-term outlook is positive for specialty chemicals and ingredients distribution, with significant value creation potential.

• Leverage reduction is a priority, targeting a direction toward 3.0x to maintain BB+ credit rating.

• Board proposes a dividend of €0.226 per share.